This resulted in a higher proportion of CD patients in remission than before dose escalation ( 88 % vs 65 % ; P = .020 ) and a decrease in the median concentration of C-reactive protein , compared with before the dose increase ( 3.2 vs 4.3 mg/L ; P < .001 ) ; these changes were not observed in patients with UC .